Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 10:13:950079.
doi: 10.3389/fimmu.2022.950079. eCollection 2022.

Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy

Affiliations
Review

Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy

Matin Ghasemi et al. Front Immunol. .

Abstract

Every type of cancer tissue is theoretically more vulnerable to viral infection. This natural proclivity has been harnessed as a new anti-cancer therapy by employing oncolytic viruses (OVs) to selectively infect and destroy cancer cells while providing little or no harm with no toxicity to the host. Whereas the primary oncolytic capabilities of OVs initially sparked the greatest concern, the predominant focus of research is on the association between OVs and the host immune system. Numerous OVs are potent causal agents of class I MHC pathway-related chemicals, enabling early tumor/viral immune recognition and cytokine-mediated response. The modified OVs have been studied for their ability to bind to dendritic cells (DCs) by expressing growth factors, chemokines, cytokines, and defensins inside the viral genome. OVs, like reovirus, can directly infect DCs, causing them to release chemokines and cytokines that attract and excite natural killer (NK) cells. In addition, OVs can directly alter cancer cells' sensitivity to NK by altering the expression levels of NK cell activators and inhibitors on cancerous cells. Therefore, NK cells and DCs in modulating the therapeutic response should be considered when developing and improving future OV-based therapeutics, whether modified to express transgenes or used in combination with other drugs/immunotherapies. Concerning the close relationship between NK cells and DCs in the potential of OVs to kill tumor cells, we explore how DCs and NK cells in tumor microenvironment affect oncolytic virotherapy and summarize additional information about the interaction mentioned above in detail in this work.

Keywords: cancer; dendritic cells; natural killer cells; oncolytic virotherapy; virus; virus immunology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
TME warming up via OV infection. In a cold tumor, several immunosuppressors could inhibit the proper anti-tumor activity of immune cells. In this case, tumorigenicity could be progressed and lead to the development of other cancer features. Proceeding an OV infection, releasing pro-inflammatory cytokines and chemokines could activate chemotaxis of lymphoid cells such as T cells and NK cells to enhance the immune response against tumor progression. Besides, by direct infection of DCs via OVs, these immune cells could trigger NK cells and support a specific cytotoxic response.
Figure 2
Figure 2
Interaction between NK cells and DCs. These two immune cells could have intermodulation and enhance the activation and migration of NK cells as well as DC maturation. Upon OV infection, DCs can increase the activity and migration of NK cells and on the other side, NK cells trigger the maturation of DCs. Hyperactivated NK cells detect pro-inflammatory cytokines and increase the immune response against cancerous cells.

Similar articles

Cited by

References

    1. Choi AH, O’Leary MP, Fong Y, Chen NG. From benchtop to bedside: A review of oncolytic virotherapy. Biomedicines (2016) 4(3):18. doi: 10.3390/biomedicines4030018 - DOI - PMC - PubMed
    1. Marelli G, Howells A, Lemoine NR, Wang Y. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Front Immunol (2018) 9:866. doi: 10.3389/fimmu.2018.00866 - DOI - PMC - PubMed
    1. Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccines immunother (2020) 16(10):2389–402. doi: 10.1080/21645515.2020.1723363 - DOI - PMC - PubMed
    1. Chaurasiya S, Chen NG, Fong Y. Oncolytic viruses and immunity. Curr Opin Immunol (2018) 51:83–90. doi: 10.1016/j.coi.2018.03.008 - DOI - PMC - PubMed
    1. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 14(10):1014–22. doi: 10.1038/ni.2703 - DOI - PMC - PubMed